1.1 	A bill for an act
1.2 	relating to human services; allowing the early periodic screening, diagnosis, and 
1.3 	treatment program to cover stiripentol; amending Minnesota Statutes 2016, section 
1.4 	256B.0625, subdivision 64.
1.5 	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.6 	Section 1. Minnesota Statutes 2016, section 256B.0625, subdivision 64, is amended to 
1.7 	read:
1.8 		Subd. 64.Investigational drugs, biological products, and devices. Medical assistance 
1.9 	and the early periodic screening, diagnosis, and treatment (EPSDT) program do not cover 
1.10 	costs incidental to, associated with, or resulting from the use of investigational drugs, 
1.11 	biological products, or devices as defined in section 151.375., except that stiripentol may 
1.12 	be covered by the EPSDT program, only if all of the following conditions are met:
1.13 	(1) the use of stiripentol is determined to be medically necessary;
1.14 	(2) stiripentol is covered only for eligible enrollees with a documented diagnosis of 
1.15 	Dravet syndrome, regardless of whether an SCN1A genetic mutation is found, or children 
1.16 	with Malignant Migrating Partial Epilepsy in Infancy due to an SCN2A genetic mutation;
1.17 	(3) all other available covered prescription medications that are medically necessary for 
1.18 	the patient have been tried without successful outcomes; and
1.19 	(4) the United States Food and Drug Administration has approved the treating physician's 
1.20 	individual patient investigational new drug application (IND) for the use of stiripentol for 
1.21 	treatment.
2.1 	This provision related to coverage of stiripentol does not apply to MinnesotaCare 
2.2 	coverage under chapter 256L.